These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37437516)

  • 1. Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL).
    Grobost V; Hammi S; Pereira B; Guilhem A; Duffau P; Seguier J; Parrot A; Gautier G; Alric L; Kerjouan M; Le Guillou X; Simon D; Chaussavoine L; Rondeau-Lutz M; Leguy-Seguin V; Delagrange L; Lavigne C; Maillard H; Dupuis-Girod S;
    Thromb Res; 2023 Sep; 229():107-113. PubMed ID: 37437516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia.
    Virk ZM; Zhang E; Rodriguez-Lopez J; Witkin A; Wong AK; Luther J; Lin AE; Ning M; Grabowski E; Holbrook EH; Al-Samkari H
    J Thromb Haemost; 2023 Jan; 21(1):26-36. PubMed ID: 36695393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia: A scoping review.
    Zhang E; Virk ZM; Rodriguez-Lopez J; Al-Samkari H
    Thromb Res; 2023 Jun; 226():150-155. PubMed ID: 37163869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation.
    Edwards CP; Shehata N; Faughnan ME
    Ann Hematol; 2012 Dec; 91(12):1959-68. PubMed ID: 23053175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
    Shovlin CL; Millar CM; Droege F; Kjeldsen A; Manfredi G; Suppressa P; Ugolini S; Coote N; Fialla AD; Geisthoff U; Lenato GM; Mager HJ; Pagella F; Post MC; Sabbà C; Sure U; Torring PM; Dupuis-Girod S; Buscarini E;
    Orphanet J Rare Dis; 2019 Aug; 14(1):210. PubMed ID: 31462308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy for atrial fibrillation in hereditary hemorrhagic telangiectasia.
    Virk ZM; Richardson TL; Al-Samkari H
    J Thromb Thrombolysis; 2023 Aug; 56(2):355-359. PubMed ID: 37340288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of reduced or absent antithrombotic therapy after left atrial appendage closure in patients affected by hereditary hemorrhagic telangiectasia and atrial fibrillation.
    Pepe M; Suppressa P; Giuliano AF; Nestola PL; Bortone AS; DE Cillis E; Acquaviva T; Forleo C; Moscarelli M; Lenato GM; Sabbà C
    Minerva Cardiol Angiol; 2022 Oct; 70(5):537-544. PubMed ID: 33703853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Rates of Bleeding Complications among Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia in the United States.
    Brinjikji W; Wood CP; Lanzino G; Cloft HJ; Misra S; Kallmes DF; Kamath P; Pruthi RK; Krowka MJ; Swanson KL; Iyer VN
    Ann Am Thorac Soc; 2016 Sep; 13(9):1505-11. PubMed ID: 27387823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry.
    Gaetani E; Agostini F; Giarretta I; Porfidia A; Di Martino L; Gasbarrini A; Pola R; On Behalf Of The Multidisciplinary Gemelli Hospital Group For Hht
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.
    Parambil JG; Gossage JR; McCrae KR; Woodard TD; Menon KVN; Timmerman KL; Pederson DP; Sprecher DL; Al-Samkari H
    Angiogenesis; 2022 Feb; 25(1):87-97. PubMed ID: 34292451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia.
    Kjeldsen AD; Kjeldsen J
    Am J Gastroenterol; 2000 Feb; 95(2):415-8. PubMed ID: 10685743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia.
    Longacre AV; Gross CP; Gallitelli M; Henderson KJ; White RI; Proctor DD
    Am J Gastroenterol; 2003 Jan; 98(1):59-65. PubMed ID: 12526937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk.
    Collette C; Clerc-Urmès I; Laborde-Castérot H; Frimat L; Ayav C; Peters N; Martin A; Agrinier N; Thilly N
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):935-43. PubMed ID: 27133538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia.
    Thompson KP; Sykes J; Chandakkar P; Marambaud P; Vozoris NT; Marchuk DA; Faughnan ME
    Orphanet J Rare Dis; 2022 Nov; 17(1):405. PubMed ID: 36344987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hereditary hemorrhagic telangiectasia: symptoms and diagnostic latency].
    Droege F; Kuerten CHL; Kaiser C; Dingemann J; Kaster F; Dahlfrancis PM; Lueb C; Zioga E; Thangavelu K; Lang S; Geisthoff U
    Laryngorhinootologie; 2021 Jun; 100(6):443-452. PubMed ID: 33761571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients.
    Abraham NS; Hartman C; Richardson P; Castillo D; Street RL; Naik AD
    Circulation; 2013 Oct; 128(17):1869-77. PubMed ID: 24025594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study.
    Donaldson JW; McKeever TM; Hall IP; Hubbard RB; Fogarty AW
    Neurology; 2015 May; 84(18):1886-93. PubMed ID: 25862798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.